Breast cancer patients are at high risk of contracting COVID-19 (coronavirus) disease. This is evident since both cancer and its treatment tend to weaken the immune system, resulting in complications arising from COVID-19. Hence, companies in the paclitaxel injection market are boosting their output capacities to avoid supply chain jolts in the healthcare industry.
As such, patients who are not actively receiving cancer treatment are also at a risk of contracting COVID-19, since the effects of the treatment are usually long lasting. Thus, companies in the paclitaxel injection market are capitalizing on such value-grab opportunities in order to keep economies running during the ongoing pandemic.
Get Brochure of the Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2025
Healthcare associations are advising cancer patients to maintain adequate delivery of medications and supplies that last for collective weeks. COVID-19 patients with breast cancer are being advised to identify any interactions with anti-cancer medications.
Cremophor and Albumin-free Formulations in Paclitaxel Injections Gain Market Recognition
Albumin-free formulations in paclitaxel injections are being preferred by clinicians to improve medical outcomes. In December 2019, Mumbai-based Sun Pharma Advanced Research Company Ltd. (SPARC)— a clinical stage bio-pharmaceutical company announced that Abraxis Bioscience LLC has withdrawn its infringement claims over the former’s Paclitaxel Injection Concentrate for Suspension (PICS). Innovative product offerings are contributing toward the growth of the paclitaxel injection market. Moreover, regulatory approvals for products are bolstering the credibility credentials of manufacturers, thus paving the way for successful launch.
Get Table of Content of the Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=2025
Cremophor® and albumin-free formulations hold promising potentials for companies in the paclitaxel injection market. Such innovative formulations are expected to boost productivity levels in hospitals, as clinicians can easily use PVC (Poly Vinyl Chloride) or non-PVC sterile infusion bags for drug delivery. Cremophor® and albumin-free formulations are expected to eliminate the need for premedication to prevent hypersensitivity.
Superior Paclitaxel Nanotechnology-driven Formulations Fuel Development of New Drugs
The paclitaxel injection market has transitioned from the use of anti-cancer drug Taxol® to incorporate Abraxane®, a human albumin-based preparation of paclitaxel. Superior paclitaxel nanotechnology-driven formulations are sparking competition among pharma companies. However, these formulations need to undergo rigorous regulatory processes, clinical evaluations, and patentability tests before launch. These factors are inhibiting the growth of the paclitaxel injection market. Hence, pharma companies should focus on new drug development with the help of R&D.
Pharma companies are increasing efforts to create availability for safe and effective drug therapies for patient satisfaction with the help of nano paclitaxel formulations. Combination therapies involving paclitaxel and doxorubicin (DOX) are being highly publicized in the healthcare landscape. These therapies are widely used in clinical practice improve anti-cancer effect of drugs and minimize adverse events.
Nanoparticle Formulations Help Improve Efficacy of Gemcitabine Chemotherapy
Pancreatic cancer is of the most lethal diseases with a poor survival rate. Such medical conditions are fueling innovations in paclitaxel injections. Gemcitabine (GEM) is considered as the gold standard for chemotherapy among pancreatic cancer patients. However, GEM-acquired resistance in cancer cells is acting as a major setback for its continued implementation. Hence, companies in the paclitaxel injection market are capitalizing on this opportunity to innovate in unique paclitaxel–poly (lactic-co-glycolic acid) (PLGA) nanoparticles (PPNPs) formulations to improve patient outcomes.
Nanoparticle formulations help to target lipid metabolism and improve efficacy of gemcitabine chemotherapy. Companies in the paclitaxel injection market are increasing their production capabilities in nanoparticle formulations to inhibit excessive lipid formulation and alter membrane stability. This molecular action is improving the efficacy of gemcitabine chemotherapy, owing to evidences of enhanced inhibitory effects on the tumorigenic assays in pancreatic cancer cells.
Get Custom Research Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=2025
Biocompatible PEG Holds Promising Potentials in Nanotherapeutic Strategies
Nanotherapeutic strategies have become a recurring trend in the paclitaxel injection market. Paclitaxel-conjugated nanofibers split into tiny nanoparticles inside the body. It is emerging as a new strategy for anticancer therapy. Nanoparticles can be loaded with therapeutic agents and later injected in the body to administer drugs safely and with greater efficacy.
Such treatment methods are reducing incidence of side effects usually common in cancer treatments. Companies in the paclitaxel injection market should collaborate with researchers from renowned universities to develop nanoparticles that remain stable in the blood to allow efficacious circulation of drug formulations in order to reach its target.
Companies are increasing focus in nanocarriers that are biocompatible. Stable nanofibers with good loading capacities are in high demand. Extensively used biodegradable and biocompatible pharmaceutical ingredients such as polyethylene glycol (PEG) hold promising potentials in nanofiber development.
Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. The firm scrutinizes factors shaping the dynamics of demand in various markets. The insights and perspectives on the markets evaluate opportunities in various segments. The opportunities in the segments based on source, application, demographics, sales channel, and end-use are analysed, which will determine growth in the markets over the next decade.
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
USA – Canada Toll Free: 866-552-3453